Skip to main content
Top
Published in: Supportive Care in Cancer 5/2016

01-05-2016 | Original Article

Symptom burden in long-term germ cell tumor survivors

Authors: Karin Oechsle, Michael Hartmann, Anja Mehnert, Christoph Oing, Carsten Bokemeyer, Sigrun Vehling

Published in: Supportive Care in Cancer | Issue 5/2016

Login to get access

Abstract

Purpose

Testicular germ cell tumor (GCT) and its treatment may cause distressing long-term symptoms. We aimed to examine self-reported symptom frequency and distress as well as the impact of demographic and medical characteristics in GCT survivors.

Methods

A total of 164 GCT survivors receiving follow-up care at the University Cancer Center Hamburg and a specialized private practice facility were interviewed at a median time of 11.6 years after first diagnosis. Metastatic disease was present in 48 % of the patients and relapse had occurred in 17 %. The patients completed the short form of the Memorial Symptom Assessment Scale (MSAS-SF) assessing 28 physical and 4 psychological symptoms.

Results

The mean number of physical symptoms was 4.5 (SD = 4.3) (psychological symptoms M = 1.4, SD = 1.4; total M = 5.9, SD = 5.2). The most frequent physical symptoms were lack of energy (49 %), feeling drowsy (42 %), sleeping problems (36 %), and difficulty in concentration (32 %). Lack of energy was experienced as highly distressing by 21 % of the patients. The most frequent psychological symptoms were irritability (47 %) and being worried (42 %). The number of physical symptoms was associated with higher age, lower socioeconomic status, and shorter time since diagnosis in multivariate regression analyses controlling for metastatic vs. localized disease, relapse, extent of surgery, number of chemotherapy cycles, and radiotherapy.

Conclusions

GCT survivors suffered from a significant number of long-term symptoms. Fatigue-related symptoms were most frequent and perceived as highly distressing. Continuous attention toward fatigue is necessary throughout follow-up care to offer support in time, particularly in more vulnerable patients of higher age and lower socioeconomic status.
Literature
1.
go back to reference Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8:1777–1781CrossRefPubMed Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8:1777–1781CrossRefPubMed
2.
go back to reference Hanna NH, Einhorn LH (2014) Testicular cancer–discoveries and updates. N Engl J Med 371:2005–2016CrossRefPubMed Hanna NH, Einhorn LH (2014) Testicular cancer–discoveries and updates. N Engl J Med 371:2005–2016CrossRefPubMed
3.
go back to reference Cleeland CS 2007. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 16–21. Cleeland CS 2007. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 16–21.
4.
go back to reference Rossen P, Pedersen AF, Zachariae R, von der Maase H (2012) Sexuality and body image in long-term survivors of testicular cancer. Eur J Cancer 48:571–578CrossRefPubMed Rossen P, Pedersen AF, Zachariae R, von der Maase H (2012) Sexuality and body image in long-term survivors of testicular cancer. Eur J Cancer 48:571–578CrossRefPubMed
5.
go back to reference Eberhard J, Ståhl O, Cohn-Cedermark G, et al. (2009) Sexual function in men treated for testicular cancer. J Sex Med 6:1979–1989CrossRefPubMed Eberhard J, Ståhl O, Cohn-Cedermark G, et al. (2009) Sexual function in men treated for testicular cancer. J Sex Med 6:1979–1989CrossRefPubMed
6.
go back to reference Orre IJ, Fosså SD, Murison R, et al. (2008) Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res 64:363–371CrossRefPubMed Orre IJ, Fosså SD, Murison R, et al. (2008) Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res 64:363–371CrossRefPubMed
7.
go back to reference Fleer J, Sleijfer DT, Hoekstra HJ, et al. (2005) Prevalence, changes in and correlates of fatigue in the first year after diagnosis of testicular cancer. Anticancer Res 25:4647–4653PubMed Fleer J, Sleijfer DT, Hoekstra HJ, et al. (2005) Prevalence, changes in and correlates of fatigue in the first year after diagnosis of testicular cancer. Anticancer Res 25:4647–4653PubMed
8.
go back to reference Fosså SD, Dahl AA, Loge JH (2003) Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 21:1249–1254CrossRefPubMed Fosså SD, Dahl AA, Loge JH (2003) Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 21:1249–1254CrossRefPubMed
9.
go back to reference Schagen SB, Boogerd W, Muller MJ, et al. (2008) Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 47:63–70CrossRefPubMed Schagen SB, Boogerd W, Muller MJ, et al. (2008) Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 47:63–70CrossRefPubMed
10.
go back to reference Haugnes HS, Bosl GJ, Boer H, et al. (2012) Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 30:3752–3763CrossRefPubMed Haugnes HS, Bosl GJ, Boer H, et al. (2012) Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 30:3752–3763CrossRefPubMed
11.
go back to reference Abouassaly R, Fosså SD, Giwercman A, et al. (2011) Sequelae of treatment in long-term survivors of testis cancer. Eur Urol 60:516–526CrossRefPubMed Abouassaly R, Fosså SD, Giwercman A, et al. (2011) Sequelae of treatment in long-term survivors of testis cancer. Eur Urol 60:516–526CrossRefPubMed
12.
go back to reference Lauritsen J, Mortensen MS, Kier MGG, et al. (2015) Renal impairment and late toxicity in germ-cell cancer survivors. Ann Oncol 26:173–178CrossRefPubMed Lauritsen J, Mortensen MS, Kier MGG, et al. (2015) Renal impairment and late toxicity in germ-cell cancer survivors. Ann Oncol 26:173–178CrossRefPubMed
13.
go back to reference Haugnes HS, Oldenburg J, Bremnes RM. Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urol Oncol 2014. [Epub ahead of print] doi: 10.1016/j.urolonc.2014.11.012 Haugnes HS, Oldenburg J, Bremnes RM. Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urol Oncol 2014. [Epub ahead of print] doi: 10.1016/j.urolonc.2014.11.012
14.
go back to reference Kjaer TK, Johansen C, Ibfelt E, et al. (2011) Impact of symptom burden on health related quality of life of cancer survivors in a Danish cancer rehabilitation program: a longitudinal study. Acta Oncol 50:223–232CrossRefPubMed Kjaer TK, Johansen C, Ibfelt E, et al. (2011) Impact of symptom burden on health related quality of life of cancer survivors in a Danish cancer rehabilitation program: a longitudinal study. Acta Oncol 50:223–232CrossRefPubMed
15.
go back to reference Harrington CB, Hansen JA, Moskowitz M, et al. (2010) It’s not over when it’s over: long-term symptoms in cancer survivors - a systematic review. Int J Psychiatry Med 40:163–181CrossRefPubMed Harrington CB, Hansen JA, Moskowitz M, et al. (2010) It’s not over when it’s over: long-term symptoms in cancer survivors - a systematic review. Int J Psychiatry Med 40:163–181CrossRefPubMed
16.
go back to reference Mykletun A, Dahl AA, Haaland CF, et al. (2005) Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 23:3061–3068CrossRefPubMed Mykletun A, Dahl AA, Haaland CF, et al. (2005) Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 23:3061–3068CrossRefPubMed
17.
go back to reference Rudberg L, Carlsson M, Nilsson S, Wikblad K (2002) Self-perceived physical, psychologic, and general symptoms in survivors of testicular cancer 3 to 13 years after treatment. Cancer Nurs 25:187–195CrossRefPubMed Rudberg L, Carlsson M, Nilsson S, Wikblad K (2002) Self-perceived physical, psychologic, and general symptoms in survivors of testicular cancer 3 to 13 years after treatment. Cancer Nurs 25:187–195CrossRefPubMed
18.
19.
go back to reference International Germ Cell Consensus Classification (1997) A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594–603CrossRef International Germ Cell Consensus Classification (1997) A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594–603CrossRef
20.
go back to reference Portenoy RK, Thaler HT, Kornblith AB, et al. (1994) The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326–1336CrossRefPubMed Portenoy RK, Thaler HT, Kornblith AB, et al. (1994) The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326–1336CrossRefPubMed
21.
go back to reference Chang VT, Hwang SS, Feuerman M, et al. (2000) The memorial symptom assessment scale short form (MSAS-SF). Cancer 89:1162–1171CrossRefPubMed Chang VT, Hwang SS, Feuerman M, et al. (2000) The memorial symptom assessment scale short form (MSAS-SF). Cancer 89:1162–1171CrossRefPubMed
22.
go back to reference Aaronson NK, Mattioli V, Minton O, et al. (2014) Beyond treatment – psychosocial and behavioural issues in cancer survivorship research and practice. Eur J Cancer 12:54–64CrossRef Aaronson NK, Mattioli V, Minton O, et al. (2014) Beyond treatment – psychosocial and behavioural issues in cancer survivorship research and practice. Eur J Cancer 12:54–64CrossRef
23.
go back to reference Cramp F, Byron-Daniel J (2012) Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 11:CD006145PubMed Cramp F, Byron-Daniel J (2012) Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 11:CD006145PubMed
24.
go back to reference Goedendorp MM, Gielissen, Marieke FM, et al. Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 2009:CD006953 Goedendorp MM, Gielissen, Marieke FM, et al. Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 2009:CD006953
25.
go back to reference Pedersen AD, Rossen P, Mehlsen MY, et al. (2009) Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 15:296–301CrossRefPubMed Pedersen AD, Rossen P, Mehlsen MY, et al. (2009) Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 15:296–301CrossRefPubMed
26.
go back to reference Skaali T, Fosså SD, Andersson S, et al. (2011) A prospective study of neuropsychological functioning in testicular cancer patients. Ann Oncol 22:1062–1070CrossRefPubMed Skaali T, Fosså SD, Andersson S, et al. (2011) A prospective study of neuropsychological functioning in testicular cancer patients. Ann Oncol 22:1062–1070CrossRefPubMed
27.
go back to reference Moreira Jr ED, Hartmann U, Glasser DB, Gingell C (2005) A population survey of sexual activity, sexual dysfunction and associated help-seeking behavior in middle-aged and older adults in Germany. Eur J Med Res 10:434–443PubMed Moreira Jr ED, Hartmann U, Glasser DB, Gingell C (2005) A population survey of sexual activity, sexual dysfunction and associated help-seeking behavior in middle-aged and older adults in Germany. Eur J Med Res 10:434–443PubMed
28.
go back to reference Nazareth I, Lewin J, King M (2001) Sexual dysfunction after treatment for testicular cancer: a systematic review. J Psychosom Res 51:735–743CrossRefPubMed Nazareth I, Lewin J, King M (2001) Sexual dysfunction after treatment for testicular cancer: a systematic review. J Psychosom Res 51:735–743CrossRefPubMed
Metadata
Title
Symptom burden in long-term germ cell tumor survivors
Authors
Karin Oechsle
Michael Hartmann
Anja Mehnert
Christoph Oing
Carsten Bokemeyer
Sigrun Vehling
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 5/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-3026-9

Other articles of this Issue 5/2016

Supportive Care in Cancer 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine